Latest Inflammatory Diseases News

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.